Cargando…

TRIM28 regulates the nuclear accumulation and toxicity of both alpha-synuclein and tau

Several neurodegenerative diseases are driven by the toxic gain-of-function of specific proteins within the brain. Elevated levels of alpha-synuclein (α-Syn) appear to drive neurotoxicity in Parkinson's disease (PD); neuronal accumulation of tau is a hallmark of Alzheimer's disease (AD); a...

Descripción completa

Detalles Bibliográficos
Autores principales: Rousseaux, Maxime WC, de Haro, Maria, Lasagna-Reeves, Cristian A, De Maio, Antonia, Park, Jeehye, Jafar-Nejad, Paymaan, Al-Ramahi, Ismael, Sharma, Ajay, See, Lauren, Lu, Nan, Vilanova-Velez, Luis, Klisch, Tiemo J, Westbrook, Thomas F, Troncoso, Juan C, Botas, Juan, Zoghbi, Huda Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104516/
https://www.ncbi.nlm.nih.gov/pubmed/27779468
http://dx.doi.org/10.7554/eLife.19809
Descripción
Sumario:Several neurodegenerative diseases are driven by the toxic gain-of-function of specific proteins within the brain. Elevated levels of alpha-synuclein (α-Syn) appear to drive neurotoxicity in Parkinson's disease (PD); neuronal accumulation of tau is a hallmark of Alzheimer's disease (AD); and their increased levels cause neurodegeneration in humans and model organisms. Despite the clinical differences between AD and PD, several lines of evidence suggest that α-Syn and tau overlap pathologically. The connections between α-Syn and tau led us to ask whether these proteins might be regulated through a shared pathway. We therefore screened for genes that affect post-translational levels of α-Syn and tau. We found that TRIM28 regulates α-Syn and tau levels and that its reduction rescues toxicity in animal models of tau- and α-Syn-mediated degeneration. TRIM28 stabilizes and promotes the nuclear accumulation and toxicity of both proteins. Intersecting screens across comorbid proteinopathies thus reveal shared mechanisms and therapeutic entry points. DOI: http://dx.doi.org/10.7554/eLife.19809.001